07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

ETBX-011: Phase I/II data

An open-label, U.S. Phase I/II trial in 25 patients with refractory advanced CEA-expressing colorectal cancer showed that subcutaneous ETBX-011 given once every 3 weeks for 3 doses led to a 1-year overall survival (OS) rate...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Clinical News

ETBX-011: Phase II started

Etubics began an open-label, U.S. Phase II trial to evaluate 3 immunization of subcutaneous ETBX-011 given every 3 weeks in 12 patients. Etubics Corp., Seattle, Wash.   Product: ETBX-011   Business: Cancer   Molecular target: NA   Description:...